AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04511832
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
Trial: NCT02057796
Drug: ART (Atripla, Truvada, Efavirenz, Combivir)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~* ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2
Trial: NCT00359021
Drug: TMC125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg twice daily until commercially available
Trial: NCT03719612
Drug: DEFINITY®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a single dose of DEFINITY®
Trial: NCT03619005
Drug: Placebo Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of a placebo vaginal insert.
Trial: NCT03619005
Drug: Prasterone 6.5 mg (0.50%) Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
Trial: NCT00865696
Drug: REMERON® 15 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
Trial: NCT02629094
Drug: Inspra /Eplerenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
Trial: NCT00705484
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
Trial: NCT02621060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 1200 mg per day for three months
Trial: NCT00567177
Drug: Restasis, Refresh Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
Trial: NCT03092206
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiretroviral therapy
Trial: NCT04329403
Drug: Differin 0.1% Topical Gel
RxNorm normalized name: Differin 0.1% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
Trial: NCT00766090
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Corticosteroid
Trial: NCT03556436
Drug: YH25448 240mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
Trial: NCT01750931
Drug: Meloxicam GSK 15mg
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \&amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
Trial: NCT02207998
Drug: Placebo and physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
Trial: NCT02132884
Drug: targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive specific targeted therapy
Trial: NCT00244387
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02981264
Drug: Transcricoid Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02086188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Mirabegron 25mg tablet.
Trial: NCT02981264
Drug: Spray as you go
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00234078
Drug: 0.5% OPC-12759
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00234078
Drug: 1% OPC-12759
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00234078
Drug: 2% OPC-12759
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00234078
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00139178
Drug: Different HAART regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02290626
Drug: Semi-solid diet
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-solid diet is administered using PEG.
Trial: NCT01536951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03471078
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator tablet
Trial: NCT00397033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 6 weeks
Trial: NCT02248597
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00078325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets once daily in the morning
Trial: NCT04587778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT03054922
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 0.9% NaCl throughout surgery.
Trial: NCT03054922
Drug: Normosol-R Inj
RxNorm normalized name: NORMOSOL-R INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of Normosol throughout surgery.
Trial: NCT04587778
Drug: Pilot study II: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01269801
Drug: JUVÉDERM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.
Trial: NCT00710736
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, escalating
Trial: NCT00710736
Drug: Capecitabine, 5-fluorouracil prodrug; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule
Trial: NCT03632590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsules will contain starch (Amylum solani) for 24 weeks
Trial: NCT03805750
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo
Trial: NCT00236769
Drug: norelgestromin + ethinyl estradiol
RxNorm normalized name: ethinyl estradiol / norelgestromin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00924105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. injection
Trial: NCT02341638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00756080
Drug: citrulline
RxNorm normalized name: Citrulline
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.06 G/kg three times/day during 7 days
Trial: NCT01124929
Drug: RNTCP Category I treatment for 6 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2H3R3Z3 E3 + 4H3R3
Trial: NCT01124929
Drug: RNTCP Category I treatment for 9months
RxNorm normalized name: Retinoids for cancer treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2H3R3Z3 E3 + 7H3R3
Trial: NCT01552291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30g oral maltodextrin / day for 5 days before surgery
Trial: NCT02447055
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02453490
Drug: 5-fluorouracil-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
Trial: NCT04310085
Drug: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
RxNorm normalized name: artemether-lumefantrine 20 mg-120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h
Trial: NCT00524862
Drug: Optimized medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
Trial: NCT00068575
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 175 mg/m\^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
Trial: NCT00890981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to denosumab subcutaneously every 6 months in the previous study
Trial: NCT00868985
Drug: PEG 3350 plus electrolytes
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
Trial: NCT00868985
Drug: PEG 3350 without electrolytes
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
Trial: NCT00868010
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
Trial: NCT05172622
Drug: JP-2266
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15
Trial: NCT05172622
Drug: JP-2266 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15
Trial: NCT00626249
Drug: Technosphere Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere Inhalation Powder
Trial: NCT02852655
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01651715
Drug: TAO1, oral homeopathic antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime).
Trial: NCT00545597
Drug: Lorenzo's oil
RxNorm normalized name: LORENZO'S OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
Trial: NCT02670070
Drug: gemigliptin 50mg, rosuvastatin 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemigliptin/rosuvastatin 50/20mg
Trial: NCT00130195
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00130195
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00153803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
Trial: NCT00130195
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00862979
Drug: Enteric coated mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 mg or 360 mg tablet dosed 1440-2280 mg per day
Trial: NCT00862979
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
Trial: NCT00384852
Drug: rhBMP-2/CPM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01533298
Drug: CombiflexOmega peri
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously over 3 days infusion
Trial: NCT00507949
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
Trial: NCT03208764
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
Trial: NCT01143727
Drug: Tegaderm Hydrogel
RxNorm normalized name: Tegaderm Hydrogel Wound Filler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply once 24-hr period sufficient to cover the wound.
Trial: NCT03588988
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
Trial: NCT00503594
Drug: Methotrexate and temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and temozolomide
Trial: NCT00503594
Drug: Methotrexate , procarbazine ,vincristine ,cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate , procarbazine ,vincristine ,cytarabine
Trial: NCT04641455
Drug: Espumisan, N acetylcystein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
Trial: NCT04641455
Drug: Espumisan, N acetylcystein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
Trial: NCT02108860
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
Trial: NCT02047539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00587470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01167725
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01167725
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01167725
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01167725
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01167725
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00397241
Drug: placebo (artificial tears)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03292653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Trial: NCT01046942
Drug: Clopidogrel+acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
Trial: NCT01046942
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 75 mg daily, started 6-24 hours after surgery
Trial: NCT01866163
Drug: LEO 90100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01866163
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00206583
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
Trial: NCT01194453
Drug: cisplatin, dexamethasone,vitamin B12, folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
Trial: NCT00228397
Drug: CCI-779
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02146261
Drug: E6011
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
Trial: NCT02146261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of placebo
Trial: NCT02008279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
Trial: NCT00525044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00959036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 4 weeks
Trial: NCT00959036
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01524198
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
Trial: NCT01183585
Drug: RO4917838 and Rosuvastatin
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
Trial: NCT01529177
Drug: Clomiphene citrate / hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
Trial: NCT00668070
Drug: ASP9831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00668070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02466867
Drug: Naftin® Cream, 2% (younger pediatric cohort)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.